AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes
AIkido Pharma Inc. (NASDAQ: AIKI) announced the successful IPO of ASP Isotopes (NASDAQ: ASPI) on November 10, 2022. The company priced 1,250,000 shares at $4.00 each, raising approximately $5.0 million in gross proceeds. The offering closed on November 14, 2022, enabling ASP Isotopes to enhance capital access and investor visibility. AIkido's CEO, Anthony Hayes, congratulated ASP Isotopes on this accomplishment, emphasizing the challenges faced in public markets. AIkido, established in 1967, focuses on developing anticancer and antiviral therapeutics through partnerships with notable universities.
- Successfully raised approximately $5.0 million from the IPO.
- Increased visibility and capital access for ASP Isotopes post-IPO.
- AIkido's diverse portfolio supports long-term growth in therapeutics.
- Dilution risk for existing shareholders from the new share issuance.
Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI
NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of
The shares began trading on the Nasdaq Capital Market LLC on Nov. 10, 2022, under the ticker symbol "ASPI", and the offering closed on about Nov. 14, 2022.
Mr. Anthony Hayes, CEO of AIkido stated, "As a shareholder of ASP Isotopes, we want to congratulate the company and their CEO, Paul Mann on successfully listing on NASDAQ. This has been one of the most challenging public markets in recent memory for new issuers. We congratulate Paul and his team for getting this public offering over the line. As a public company, ASP will benefit from access to capital, broader investor outreach and engagement, and greater visibility for its customers and partners. We hope to have other companies where we are a shareholder to follow ASPI's lead in the near future.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company's platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Contact: | |
Investor Relations: | Hayden IR |
Brett Maas, Managing Partner | |
Phone: (646) 536-7331 | |
Email: brett@haydenir.com | |
AIkido: | Phone: 212-745-1373 |
Email: investorrelations@AIkido.com | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/aikido-pharma-announces-successful-initial-public-offering-of-asp-isotopes-301685906.html
SOURCE AIkido Pharma Inc.
FAQ
What did AIkido Pharma announce on November 28, 2022?
How many shares were offered in ASP Isotopes' IPO?
What were the gross proceeds from the ASP Isotopes IPO?
What is the ticker symbol for ASP Isotopes?
What are the potential benefits of the IPO for ASP Isotopes?
